Interested in a PrEP study? This is a study exploring a new, investigational HIV PrEP medication, Lenacapavir. This medication is given as an injection just under the skin, every 6 months or twice a year. We would like to find out how effective this new, investigational medication is in preventing HIV, in the hopes of expanding access and options for HIV PrEP.

The OBS-C study is an observational study that is enrolling participants that test positive AND negative to COVID-19. This study is analyzing multiple aspects of COVID-19 in people that TEST POSITIVE, including but not limited to the epidemiology and risk factors associated with SARS-CoV-2 infection, how the disease affects someone's immune system, and the various symptoms and ways the illness is displayed in the body. The study would also like to enroll a few people that TEST NEGATIVE, but have symptoms of a respiratory illness, in order to determine the reliability of the test.

Have you been diagnosed with a sexually transmitted infection or are living with HIV? You may be able to take part in a research study to understand how HIV care and prevention in the community can be improved.

Have you been infected with COVID-19? Are you a solid organ transplant recipient? Have you or your child received a COVID-19 vaccine or are planning to receive one? If so, you may be eligible to participate in a research study that will assess your immune response to COVID-19 infection or vaccination over a 5 year period. We are looking for children and adults aged 7-95 years, and plan to collect blood every 2-6 months over the study period. (Compensation provided for the first year).

This project seeks to adapt and test the existing Tough Talks app to address COVID vaccine hesitancy among African American young adults (AA-YA) aged 18-29.

In this study, we want to learn more about a program (STOMP) designed to improve chronic pain in people living with HIV.

The purpose of this study is to conduct interviews to hear people's thoughts and feedback on various aspects of conducting syphilis vaccine research at UNC-Chapel Hill and to ask them to complete a brief online survey after their interviews. The information that participants provide will help the clinical trial researchers to better understand what concerns people might have about syphilis vaccine research and to design clinical trials that are acceptable to potential vaccine research participants.

This study is testing Islatravir (MK-8591) as an oral Preexposure Prophylaxis (PrEP) drug (a drug to help prevent getting HIV) in women who are at risk for getting an HIV-1 infection. MK-8591 is a type of long-lasting drug that will only have to be taken once a month. This study will compare the safety and effectiveness of MK-8591 (Islatravir) compared to FTC/TDF (Truvada).

Vaccination for hepatitis B in individuals living with HIV does not always work, especially in those with impaired immune systems or ability to fight infection. Prevention of hepatitis B in individuals living with HIV has primarily been done by vaccinating with a series of 3 shots given over 6 months. A new vaccine, called HEPLISAV-B, has been approved that may provide a better response than what has currently been used. The researchers will study whether this vaccine will prove to be more effective than the current standard.

The purpose of this research study is to learn from YMSM about their perceptions of two phone apps designed to increase HIV testing, PrEP uptake, and other prevention strategies. We also want to learn about whether the apps encourage behavior change, as they are designed to do.